Saxagliptin, Alogliptin Linked to Heart Failure, FDA Says

Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, the FDA said April 5.

The agency said that as a result of these findings, it’s adding new warnings to the labels of these drugs. These medicines include AstraZeneca’s Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin extended release), and Takeda’s Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone).

The FDA said it evaluated two large clinical trails conducted in heart disease patients. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee also ...